CRISM: Quebec-Atlantic node
The Quebec-Atlantic Node plans to contribute to the CRISM consortium with projects that accelerate the transfer of scientific knowledge towards the development of new treatments, including pharmaceutical approaches and psychological interventions for drug users.
The Node's Researchers and collaborators have developed different areas of expertise that will inform multi-site observational studies and randomized controlled clinical trials (RCT) on the various care options for people with a substance misuse problem, as well as on the development and evaluation of new evidenced-based preventive methods, through grants funded by CIHR and other provincial and international financing bodies.
The team includes researchers from several universities and institutions, clinicians, policy makers, administrators, practitioners, and representatives of substance users groups as well as individuals in different stages of support programs for persons living with substance misuse problems in the Atlantic Provinces and Quebec. The collaboration of the two major associations (AIDQ, AQCID) brings together stakeholders and organizations working in addiction prevention, rehabilitation, therapy, hospitals and our network of community partners, allowing our pole to extend beyond the urban centres. Priority is given to the most vulnerable populations such as women who inject, youth at risk, Aboriginal people in correctional facilities, and those transitioning from rural to inner-city environments.
Nominated Principal Investigator
Julie Bruneau, M.D M.Sc; Professor of Family and Emergency Medicine at the Université de Montréal, firstname.lastname@example.org
She is a Professor of Family and Emergency Medicine at the Université de Montréal, currently Head of the Primary Care Department at the Centre Hospitalier de l'Université de Montréal (CHUM), and co-director of the CIHR-funded National Canadian Research Training Program on Hepatitis C. She is recognized as a leader in addiction medicine in Canada, and was central in the development of the Opiate Substitution treatment (OST) and Syringe Distribution Program networks in Quebec.
- Patricia Conrod, PhD, University of Montreal, Department of Psychiatry, email@example.com
- Didier Jutras-Aswad, PhD, University of Montreal, Department of Psychiatry, firstname.lastname@example.org
- Janus Kaczorowski, MD, University of Montreal, Department of Family/Emergency Medicine, email@example.com
- Gilles Lavigne, MD, University of Montreal, Department of Oral Health, firstname.lastname@example.org
- Guy Pierre Lévesque, Principal Knowledge user | PLWSMU representative, email@example.com
- Michel Perreault, PhD, McGill University, Department of Psychiatry, firstname.lastname@example.org
- Élise Roy, MD,Université de Sherbrooke, Faculty of Health and Medicine sciences, email@example.com
- Sherry Stewart, PhD, Dalhousie University, Department of Psychology and Neuroscience, firstname.lastname@example.org
The overarching goal of the Quebec-Atlantic node is to provide a dynamic research environment where partners are engaged to identify crucial needs and priorities, and work together toward the development and implementation of intervention research in the area of substance misuse. The integration of regional research activities will facilitate national and international high quality, integrated, multisite research projects. The Quebec-Atlantic node priorities will focus around development, evaluation and dissemination of interventions along four themes: poly-substance use problems; mental health comorbidities; pain; and medical comorbidities.
Node program consists of these complimentary activities
- Demonstration projects: A first demonstration project will focus on novel personality-targeted interventions to address polysubstance misuse amongst methadone maintenance clients recruited in two provincial jurisdictions (Nova Scotia and Quebec). A second demonstration project will evaluate a peer-to-peer training and intervention program, initiated by a community-based organization, whose objectives are to increase access to naloxone for the prevention of opioid overdose, and to test the capacity for community-initiated projects to implement results.
- The Quebec-Atlantic Node (QAN) wants to act as a catalyst for its members, and support their research projects that reflect the node’s priorities. We have established a working group structure as an integration mechanism to favor researchers and knowledge users involvement and research development program to support our members in an increasingly competitive research grant landscape. This Research development is part of the key to our nodes growth by contributing node resources to promising research protocol that have a better chance at receiving funding thus creating opportunities to grow the node and network through research.
- National Research projects: whether it be the OPTIMA trial or the National Guideline on the clinical management of Opioid Use disorder, The Quebec-Atlantic node is committed to strong research collaborations with its counter nodes to contribute to evidence base knowledge on opioid use disorder interventions.
Dr Julie Bruneau, Director & NPI
Tel.: 1-514-890-8000 ex. 30936
Aïssata Sako, Research operations and project manager
Tel.: 514 890-8000 ext. 30936
- Date modified: